1. Introduction {#sec1}
===============

Head and neck squamous cell carcinoma is the sixth most common malignancy worldwide. Sinonasal squamous cell carcinomas (SSCC) are rare tumor, estimated to account for approximately 3--6% of all head and neck squamous cell carcinomas. SSCC originate in the respiratory epithelium of the sinonasal cavities \[[@B1]\]. Approximately 60% of SSCC arise in the maxillary sinus, 20--30% in the nasal cavity, 10--15% in the ethmoid sinuses, and \~1% in the frontal and sphenoid sinuses \[[@B2], [@B3]\]. Environmental factors, such as wood dust and textile, may play a critical role in the development of SSCC. As in other head and neck squamous cell carcinomas, smoking is a known risk factor \[[@B4]\]. Males who have greater occupational exposure to carcinogens are affected twice as often as females. It is controversial that chronic inflammatory sinus disease could influence development of SSCC. Human papilloma virus (HPV) types 16 and 18 may be implicated in malignant transformation of inverted papillomas \[[@B5]\]. The low incidence of SSCC combined with their nonspecific symptoms often leads to a critical delay in diagnosis. Treatment for SSCC is usually primarily surgical with adjuvant radiotherapy and sometimes with adjuvant chemotherapy for all except small tumors \[[@B1]\]. Surgical management of SSCC is of great challenge due to its anatomical complexity, especially advanced SSCC involving eye, skull base, or infratemporal fossa. In spite of major advances in the therapy of SSCC, including surgery and chemoradiotherapy methods, the 5-year survival rate is still very low (30--50%) \[[@B1]\].

Long noncoding RNAs (lncRNAs) are a subset of noncoding RNAs \>200 nucleotides in length and do not encode any protein. Due to the poor evolutionary conservation relative to the protein coding regions of the genome, lncRNAs were once considered as transcriptional noise or junk and have not been well studied historically. Recently, considerable evidence has been accumulating showing that aberrant expression of lncRNAs contributes to the development of human cancers \[[@B6]--[@B8]\]. lncRNAs contribute to tumor development through numerous different cellular processes, ranging from transcriptional and posttranscriptional regulation of relevant genes to the control of cell cycle distribution, cell differentiation, and epigenetic modifications. lncRNAs may be involved in cell proliferation, tumor invasion, metastasis, or apoptosis process. lncRNAs are pervasively transcribed and have a critical role in genome regulation \[[@B6], [@B7], [@B9]\]. However, to our knowledge, little is known about lncRNAs expression profile in SSCC, and the potential pathways regulating SSCC invasiveness remain poorly understood.

This pilot study aimed to identify aberrantly expressed lncRNAs profile of SSCC and explore their potential functions. This study will help us to understand the tumorigenesis and development of SSCC and provide some new biomarkers that may be critical to the developmental cascade.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Tissue Samples {#sec2.1}
--------------------------------

A total of 28 pairs of primary SSCC tissues and their paired adjacent noncancerous sinonasal tissues were surgically obtained from adult patients undergoing treatment at Anzhen Hospital and Tongren Hospital (two tertiary academic centers in Beijing, China) between January 2013 and August 2014. During surgery, fresh tumor tissue and paired noncancerous tissue isolated from at least 2 cm away from the tumor border (sometimes contralateral normal sinonasal mucosa) were collected in the operating room and processed immediately in liquid nitrogen within 15 minutes and then stored in RNA Fixer Reagent (Bioteke, Beijing, China) at −80°C prior to total RNA extraction. 6 pairs of tissues underwent microarray analysis ([Table 1](#tab1){ref-type="table"}) and the remaining 22 tissues were used in validation studies by quantitative real-time polymerase chain reaction (qRT-PCR). Tobacco smoke was the most common exposure factor, about 66.67% (4/6) in the microarray analysis series and 63.64% (14/22) in the PCR validation series. Wood dust was the second common exposure factor, about 33.33% (2/6) in the microarray analysis series and 18.18% (4/22) in the PCR validation series. Other exposure factors were chronic sinusitis (3/22) and leather dust (1/22). All cases were reviewed by two or more independent pathologists, and none of the patients had been previously treated with radiotherapy or chemotherapy. All tumor staging was determined according to the tumor-node-metastasis (TNM) staging criteria of American Joint Committee on Cancer (AJCC), 2010.

The Ethics Committee in Clinical Research of Capital Medical University approved this study, and written informed consent was provided by all patients.

2.2. Transcript Analysis {#sec2.2}
------------------------

RNA extraction was carried out using standard methods (Life Technologies; RNA Easy, Qiagen, Valencia, CA, USA). Total RNA was quantified by the NanoDrop ND-2000 (Thermo Scientific) and RNA integrity was assessed using Agilent Bioanalyzer 2100 (Agilent Technologies).

Microarray profiling was conducted with the Agilent Human lncRNA (4*∗*180 K, Design ID: 062918) in this experiment and data analysis of the 12 samples has been completed in the laboratory of the KPS Biotechnology Company in Beijing, China. The sample labeling, microarray hybridization, and washing were performed based on the manufacturer\'s standard protocols. Briefly, total RNA was transcribed to double strand cDNA and then synthesized into cRNA and labeled with Cyanine-3-CTP. The labeled cRNAs were hybridized onto the microarray. After washing, the arrays were scanned with the Agilent Scanner G2505C.

Feature Extraction software (version 10.7.1.1, Agilent Technologies) was used to analyze array images to obtain raw expression data, which was processed using GeneSpring. Briefly, raw data was normalized with the quantile algorithm. Probes which had at least 1 out of 2 conditions having 75% flags in "*p*" were selected for further data analysis. Differentially expressed gene transcripts were later identified. We set a standard threshold set for up- and downregulated genes of a fold change ≥2.0 and a *p* value ≤0.05.

Hierarchical clustering was performed to display expression patterns among samples. Briefly, we calculated the distance matrix between the gene expression data. Once this matrix of distances was computed, clustering begins. Agglomerative hierarchical processing consisted of repeated cycles where the two closest remaining items (those with the smallest distance) are joined by a node/branch of a tree, with the length of the branch set to the distance between the joined items. The two joined items were removed from the list of items being processed and replaced by an item that represents the new branch. The distances between this new item and all other remaining items were computed, and the process was repeated until only one item remained.

2.3. lncRNA-mRNA Coexpression Networks {#sec2.3}
--------------------------------------

*R* function cor. test (a test for association/correlation between paired samples) was utilized to compute Pearson\'s correlation coefficient to measure the gene coexpression. The lncRNAs/mRNAs (Pearson correlation coefficients ≥0.93) were selected to draw the network with Cytoscape.

According to these data, we built lncRNA-mRNA network using the correlation coefficients to examine interactions between lncRNA and mRNA. The value of "degree" in coexpression network indicated that one mRNA/lncRNA might be correlated with several lncRNAs/mRNAs.

2.4. GO Analysis and KEGG Pathway Analysis {#sec2.4}
------------------------------------------

GO analysis was applied to analyze the main function of the differential expression genes according to the GO database. Pathway analysis was used to find out the significant pathway of the differential genes according to KEGG. We used Fisher\'s exact test and *χ* ^2^ tests to select the significant pathway, and the threshold of significance was defined by *p* value and false discovery rate (FDR). The enrichment Re was calculated using standard methods with a *p* value (hypergeometric-*p* value) denoting the significance of the pathway correlated with the conditions, with a threshold of *p* \< 0.05, adjusted for multiple comparisons.

2.5. Gene Signal-Network {#sec2.5}
------------------------

Gene-gene interaction network was constructed based on the data of differentially expressed genes. Java was utilized to build and analyze molecular networks. After parsing the whole KEGG database, selected genes involved in relevant pathways were extracted, and the study pathway network was generated with the help of the pathway topology in the KEGG database.

2.6. qRT-PCR Analysis {#sec2.6}
---------------------

Total RNA was extracted and purified using standard methods (Life Technologies; RNA Easy, Qiagen, Valencia, CA, USA). M-MLV reverse transcription (Promega) was utilized to synthesize cDNA. 5 lncRNA expressions in sinonasal tissues were measured by qRT-PCR which was performed on the ABI 7500 qPCR system with the primer pairs listed in [Table 2](#tab2){ref-type="table"}. The raw quantifications were normalized to the beta-actin gene values for each sample and fold changes were shown as mean ± SD in three independent experiments, each in triplicate.

2.7. Statistical Analysis {#sec2.7}
-------------------------

All data were expressed as the mean ± SD or proportions where appropriate. Expression levels between SSCC tissues and adjacent nontumor tissues were analyzed by paired-sample *t*-tests. *p* values \<0.05 (two-tailed) indicated statistical significance. The Statistical Program for Social Sciences (SPSS) 21.0 software (SPSS, Chicago, IL, United States) was employed to perform all of the statistical analyses.

3. Results {#sec3}
==========

3.1. Overview of lncRNA Profile {#sec3.1}
-------------------------------

Out of a collection of 78,243 lncRNAs and 32,776 mRNAs probes, our lncRNA expression profile of 6 malignant sinonasal tissue and corresponding normal tissue samples from patients with SSCC indicated dysregulation of 6.73% (821 upregulated and 1103 downregulated transcripts) of mRNA and 4.02% (1174 upregulated and 1098 downregulated transcripts) of lncRNA transcripts in SSCC tissues (fold change \>2, *p* \< 0.05) ([Figure 1](#fig1){ref-type="fig"}). As expected, the lncRNA and mRNA expression profiles allowed distinguishing malignant and normal tissue samples accurately based on the molecular signature.

Out of the group of RNAs that were upregulated, lncRNA NONHSAT096777 and mRNA HORMAD1 showed the greatest degree of demonstrated upregulation, with 212.076- and 91.757-fold increases, respectively; of those that were downregulated, lncRNA TCONS_l2_00002973 and mRNA ANKRD30A demonstrated the greatest degree of downregulation, with 298.204- and 275.902-fold decreases, respectively (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}).

Hierarchical clustering of the lncRNAs and mRNAs profile was performed using cluster 3.0.2; hierarchical clustering of the expression of the top 100 dysregulated lncRNAs and top dysregulated 100 mRNAs based on centered Pearson correlation clearly separated SSCC tissues from corresponding normal tissues ([Figure 2](#fig2){ref-type="fig"}).

3.2. lncRNA-mRNA Coexpression Network {#sec3.2}
-------------------------------------

We constructed the lncRNA-mRNA coexpression network to identify the interactions between mRNAs and lncRNAs. The results showed that the coexpression network was composed of 787 network nodes and 8478 connections between 445 lncRNAs and 342 mRNAs. Within this coexpression network, 7635 pairs connections presented as positive, and 843 pairs connections presented as negative ([Figure 3](#fig3){ref-type="fig"}). This coexpression network indicated that one lncRNA (NONHSAT041869) could target 118 mRNAs/mRNAs at most and one mRNA (EXO1) could correlate with 122 lncRNAs/mRNAs at most. The results implied that EXO1, CDCA5, and BUB1B may play key roles in SSCC process and development.

3.3. Function Analysis of Differentially Expressed Genes {#sec3.3}
--------------------------------------------------------

Functional roles of lncRNAs can only be indirectly predicted by analyzing the functions of their coexpressed mRNAs, because most lncRNAs\' functions have not yet been defined. To investigate underlying biological associations, we ran GO and KEGG pathway analysis on the top 500 differentially expressed lncRNAs and mRNAs. GO analysis indicated that these differentially expressed genes were enriched in 12 biological processes; the majority were proven to be related to cancer-associated biological behaviors; the top 3 were multicellular organismal development, mitotic cell cycle, and cell cycle. The differentially expressed genes also were enriched in 12 cellular components; the top 3 were nucleus, extracellular region, and cytosol. Similarly, 12 molecular functions were enriched for including protein binding, DNA binding, and ATP binding. KEGG analysis revealed pathways associated with cancer, such as microRNAs in cancer, p53 signaling pathway, and PI3K-Akt signaling pathway (Figures [4(a)](#fig4){ref-type="fig"}--[4(d)](#fig4){ref-type="fig"}).

3.4. Gene Signal-Network {#sec3.4}
------------------------

We performed a signal-net analysis to investigate the global network, based on the significantly regulated KEGG. With signal-net, we screened the important dysregulated genes involved in the differences between SSCC and normal tissues ([Figure 5](#fig5){ref-type="fig"}). The results showed that the core genes may have played an important role in SSCC process. According to the results of this analysis, the top 3 betweenness genes were*MAPK12, RAPGEF3*, and*KIT.*

3.5. qRT-PCR Validation {#sec3.5}
-----------------------

Five differentially expressed lncRNAs were randomly selected for validation by means of qRT-PCR according to the manufacturer\'s recommendations. NONHSAT125629 and TCONS_l2_00030809 were upregulated and NONHSAT066780, NONHSAG040260, and NONHSAG043195 were downregulated in SSCC. The results of qRT-PCR were consistent with those of the microarray. All of the 5 lncRNAs were differentially expressed with the same trend (up- or downregulated) ([Figure 6](#fig6){ref-type="fig"}).

4. Discussion {#sec4}
=============

SSCC is a rare disease arising in the epithelium of respiratory tract and is very poorly studied from the molecular perspective. To date, the pathogenesis of SSCC remains unclear due to its low incidence. Only a few studies have focused on its pathogenesis and potential molecular targets for therapy, specifically microRNAs \[[@B10]--[@B12]\]. Recently, studies have increasingly shown that many types of tumors are closely associated with the abnormal expression of lncRNAs \[[@B6]--[@B9]\]. In head and neck cancer, tongue cancer \[[@B13]\], laryngeal cancer \[[@B14]\], nasopharyngeal cancer \[[@B15]\], and thyroid cancer \[[@B6]\] are all associated with the abnormal expression of lncRNAs. However, to the best of our knowledge, there are no reports on lncRNA expression profiles in SSCC.

Here, we investigated the lncRNA and mRNA expression profiles of SSCC samples from patients using microarray analysis. We identified thousands of lncRNAs that are expressed significantly differently in SSCC compared to adjacent noncancerous tissues, including both upregulation and downregulation. To some extent, false positive results do exist in the microarray detection. Therefore, 5 lncRNAs were randomly selected to validate the microarray results. Consistent with the microarray results, all of the 5 lncRNAs were differentially expressed based on the results of qRT-PCR.

In this study, we used GO and KEGG pathway analyses to identify biological functions enriched among the differentially expressed mRNAs. We found that these mRNAs were involved in a lot of cancer-associated biological processes, cellular components, and molecular functions. The GO annotation indicated that these gene products may affect the tumorigenesis and development of SSCC. The KEGG pathway analysis identified that many pathways were related to cancer, such as microRNAs in cancer, P53 signaling pathway, PI3K-Akt signaling pathway. For example, it has been documented that the p53 signaling pathway is activated in many solid tumors, including SSCC \[[@B1], [@B16], [@B17]\]. In the present study, p53 signaling pathway was related to lncRNA NONHSAT125629. This molecule may participate in numerous biological processes, including mitotic cell cycle, cell division, DNA replication, G1/S transition of mitotic cell cycle, and G2/M transition of mitotic cell cycle.

The global network (gene signal-network) and lncRNA-mRNA network structure analysis were established to show the core genes that play a critical role in this SSCC gene network. However, how these genes participate in the pathogenesis of SSCC largely remains unknown. The analysis revealed that MAPK12, RAPGEF3, and KIT exhibited the most betweenness centrality and all were related to the cancer progression. Thus, our preliminary data provide a justification for the involvement of these genes in SSCC development. For example, KIT is associated with various pathways related to cancer, such as pathways in cancer and PI3K-Akt signaling pathway. Mutations in this gene are associated with gastrointestinal stromal tumors \[[@B18]\], lung cancer \[[@B19]\], and breast cancer \[[@B20]\].

The limitation of this study lies in the fact that the sample size is relatively small. Our results require further validation in larger prospective patient cohorts and functional experiments, both*in vitro* and*in vivo*. Our results provide some valuable clues for future function and mechanism studies of SSCC.

5. Conclusions {#sec5}
==============

In summary, to our knowledge, our study is the first screening and analysis of lncRNA expression profile in SSCC. The results show that genes regulated by these lncRNAs are involved in cancer pathways as a proof of principle. This may offer new insights into pathogenesis and could be a promising way to dissect the molecular pathogenesis of this refractory cancer. Our study lays the foundation for further investigation of this disease. Further large scale studies are warranted to provide convincing evidence for clarifying the functions of lncRNAs in SSCC and determining whether these lncRNAs can serve as new diagnostic biomarkers, prognostic factors for survival, and therapeutic targets in SSCC.
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![(a) Brief microarray results of lncRNAs. Expression levels of 78,243 lncRNAs were assessed in 6 pairs of SSCC tissues and paired adjacent noncancerous sinonasal tissues using Agilent Human lncRNA 4*∗*180 K microarrays. Compared with paired adjacent noncancerous tissues, 3146 lncRNAs (4.02%) had significant changes in expression levels (fold change \>2, *p* \< 0.05). A total of 874 lncRNAs were excluded due to low expression levels. A total of 3146 lncRNAs were then identified from the screen, with 1174 upregulated and 1098 downregulated. (b) Brief microarray results of mRNAs. Expression levels of 32,776 mRNAs were assessed in 6 pairs of SSCC tissues and paired adjacent noncancerous sinonasal tissues using Agilent Human lncRNA 4*∗*180 K microarrays. Compared with paired adjacent noncancerous tissues, 2208 mRNAs (6.73%) had significant changes in expression levels (fold change \>2, *p* \< 0.05). A total of 284 mRNAs were precluded due to low expression levels. A total of 2208 lncRNAs were then identified from the screen, with 821 upregulated and 1103 downregulated.](BMRI2016-1095710.001){#fig1}

![Heat map of lncRNAs and mRNAs that were often aberrantly expressed in SSCC compared with paired adjacent noncancerous sinonasal tissues. (a) Hierarchical clustering analysis of the top 100 dysregulated lncRNAs. (b) Hierarchical clustering analysis of the top 100 dysregulated mRNAs. Each row represents one lncRNA or mRNA, and each column represents one tissue sample. The relative lncRNA or mRNA expression is depicted according to the color scale. Red indicates elevated expression and green indicates reduced expression. 2, 0 and −2 are fold changes in the corresponding spectrum. Carcinoma group (A3, F5, D6, F2, F9, and D2). Paired adjacent noncancerous group (D9, F1, G10, B2, G2, and H2).](BMRI2016-1095710.002){#fig2}

![lncRNA-mRNA coexpression network. The SSCC consisted of coexpression relationships between lncRNAs and mRNAs. The red circles denote mRNAs and the blue circles denote lncRNAs. The node degree is indicated by the circle size. An edge represents a coexpression relationship between mRNA and a lncRNA in the context of SSCC progression.](BMRI2016-1095710.003){#fig3}

![GO and KEGG pathway analysis. (a)--(c) Top 10 enrichment GO terms for differentially expressed mRNAs. The bar plot shows the enrichment scores (−lg(*p* value)) of the significant enrichment GO terms. (a) GO terms of biological process (BP); (b) GO terms of cellular component (CC); (c) GO terms of molecular function (MF). (d) Top 10 pathways of differentially expressed mRNAs in SSCC. The vertical axis represents the pathway category and the horizontal axis represents the enrichment score (−lg(*p* value)) of the pathway.](BMRI2016-1095710.004){#fig4}

![Signal-net. The interaction network of differentially expressed genes (signal-net). The circles represent important functional genes in SSCC (blue: downregulated genes; red: upregulated genes); the circle size represents the degree of interaction (betweenness centrality); the lines indicate the interactions.](BMRI2016-1095710.005){#fig5}

![qRT-PCR validation. qRT-PCR verification of 5 candidate lncRNAs in 22 pairs of SSCC tissues. The *y*-axis represents the relative expression levels of lncRNAs. Paired *t*-tests (2-tailed) were performed to compare the expression levels between carcinoma (C) and noncancerous tissues (N), and a *p* value \<0.05 indicated statistical significance.](BMRI2016-1095710.006){#fig6}

###### 

Clinical parameters of 6 SSCC patients that underwent lncRNA expression profiling.

  -------------------------------------------------------------------------------------------------------------------------------------------------
  Specimen number of\   Gender   Age (years)   Exposure factor   TNM stage   Histologic differentiation   Specimen number of noncancerous tissues
  SSCC tissues                                                                                            
  --------------------- -------- ------------- ----------------- ----------- ---------------------------- -----------------------------------------
  F5                    Male     81            Wood dust         T1N0M0      Well                         G2

  F9                    Male     46            Tobacco smoke     T3N0M0      Poorly                       G10

  A3                    Male     52            Tobacco smoke     T4N0M0      Moderately                   B2

  D6                    Male     72            Wood dust         T4N0M0      Moderately                   F1

  F2                    Male     52            Tobacco smoke     T3N0M0      Moderately                   H2

  D2                    Male     66            Tobacco smoke     T3N0M0      Moderately to Poorly         D9
  -------------------------------------------------------------------------------------------------------------------------------------------------

###### 

The primer sequences in the present study.

  lncRNA name         Forward primers (5′-3′)   Reverse primers (5′-3′)   Amplicon size (bp)
  ------------------- ------------------------- ------------------------- --------------------
  NONHSAT066780       GGAACCAGCTACTCCACACC      CCTACCCAGGCCAAGTTCTG      182
  TCONS_l2_00030809   TGAAAAACCACAGGCCCACT      ACAAACATGTCTCTCATCAGCAC   78
  NONHSAT125629       GATTTGAATCGGTCGGCGG       AGGCATTTCCTCTCACGCC       284
  NONHSAG040260       ATGCCCTACGAATGTGGACC      TCGGCCCACTGCTAAACATC      218
  NONHSAG043195       GGGAAGGCTGCCTATGAAGG      AATTCGGGGTTGCAGGTTCT      184

###### 

Top 20 aberrantly expressed lncRNAs in microarray for 6 pairs of SSCC and paired adjacent noncancerous sinonasal tissues.

  Probe name               *p*            FC (abs)   Regulation   ncRNA accession     Gene symbol     Chr
  ------------------------ -------------- ---------- ------------ ------------------- --------------- -------
  CUST_13287_PI429545395   0.019137       239.3843   Down         NONHSAT096777       STATH           chr4
  CUST_21727_PI429545388   0.039463       84.90894   Down         NONHSAT009094       PIGR            chr1
  CUST_76033_PI429545399   0.024086       82.32558   Down         NONHSAT013344       MSMB            chr10
  CUST_5401_PI429545406    0.024154       78.48107   Down         NONHSAG018364       NONHSAG018364   chr16
  CUST_82017_PI429545376   9.06*E* − 04   76.64131   Down         TCONS_l2_00029708   linc-RUSC2      chr9
  CUST_13257_PI429545395   0.019957       75.85599   Down         NONHSAT096773       STATH           chr4
  CUST_13277_PI429545395   0.023234       74.90795   Down         NONHSAT096776       STATH           chr4
  CUST_30951_PI429545395   9.49*E* − 05   67.20975   Down         NONHSAT100745       CTD-2351A8.1    chr5
  CUST_91115_PI429545399   0.04924        65.20921   Down         NONHSAT017390       MUC5B           chr11
  CUST_5411_PI429545406    0.020191       56.05385   Down         NONHSAT147874       ZG16B           chr16
  CUST_17568_PI429545406   0.02086        53.66862   Down         NONHSAT143547       HP              chr16
  CUST_32391_PI429545395   0.001238       51.26765   Down         NONHSAT101166       C7              chr5
  CUST_57295_PI429545380   1.32*E* − 04   49.87698   Down         FR352905            FR352905        chr19
  CUST_15837_PI429545395   7.74*E* − 04   47.76275   Down         NONHSAT097405       MMRN1           chr4
  CUST_32401_PI429545395   0.001893       41.53056   Down         NONHSAT101168       C7              chr5
  CUST_58955_PI429545388   1.03*E* − 05   40.74976   Up           NONHSAT075623       HOXD11          chr2
  CUST_72258_PI429545388   2.00*E* − 04   39.85786   Down         NONHSAT087567       CHL1            chr3
  CUST_58985_PI429545388   5.09*E* − 06   38.35      Up           NONHSAT075626       HOXD10          chr2
  CUST_32370_PI429545395   0.007453       33.21905   Down         NONHSAG040260       NONHSAG040260   chr5
  CUST_24853_PI429545410   0.003046       31.34336   Down         XR_253519.1         LOC101928556    N/A

FC, fold change; Chr, chromosome; N/A, not annotated.

###### 

Top 20 aberrantly expressed mRNAs in microarray for 6 pairs of SSCC and paired adjacent noncancerous sinonasal tissues.

  Probe name      *p*            FC (abs)   Regulation   Gene symbol   Chr     Genbank accession
  --------------- -------------- ---------- ------------ ------------- ------- -------------------
  A_33_P3265783   0.015708       379.6405   Down         STATH         chr4    NM_003154
  A_23_P154784    0.043979       159.44     Down         BPIFB1        chr20   NM_033197
  A_33_P3300312   0.034496       146.1192   Down         DMBT1         chr10   NM_007329
  A_24_P844984    0.030927       119.5701   Down         PIGR          chr1    NM_002644
  A_23_P86599     0.023373       95.27439   Down         DMBT1         chr10   NM_007329
  A_24_P146683    0.032317       89.55136   Down         MSMB          chr10   NM_002443
  A_33_P3216570   0.003716       75.59971   Down         MUC5AC        N/A     AJ298317
  A_23_P218369    3.92*E* − 04   73.96607   Down         CCL14         chr17   NM_032963
  A_23_P118203    0.017284       68.04929   Down         ZG16B         chr16   NM_145252
  A_21_P0013344   0.032196       61.89528   Down         AZGP1         chr7    NM_001185
  A_23_P95930     6.01*E* − 05   58.4917    Up           HMGA2         chr12   NM_003483
  A_32_P173662    0.002064       58.24841   Down         CRISP2        chr6    NM_003296
  A_23_P362694    0.036618       54.65685   Down         C4orf7        chr4    NM_152997
  A_33_P3245228   0.031988       52.29204   Down         BPIFA1        chr20   NM_130852
  A_23_P58228     0.017304       50.18366   Down         ODAM          chr4    NM_017855
  A_23_P429998    1.13*E* − 04   48.27517   Down         FOSB          chr19   NM_006732
  A_33_P3233040   0.012252       42.21305   Down         SERPINB11     chr18   NM_080475
  A_23_P8702      0.018377       40.33374   Down         PIP           chr7    NM_002652
  A_33_P3275702   1.49*E* − 05   33.86336   Down         FMO2          chr1    NM_001460
  A_21_P0000003   0.006532       31.00913   Down         PRR4          chr12   NM_007244

FC, fold change; Chr, chromosome; NA, not annotated.
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